Debate on the best first-line treatment for unmutated CLL: opinions from across the Atlantic
Overview of research in Waldenström’s macroglobulinemia therapies
Reducing the risks of chemotherapy in IGHV-mutated CLL
Round table with Prof. John Gribben and Prof. Stephan Stilgenbauer on CLL
John Gribben et al.
The first in-human Phase I study of a BET inhibitor for the treatment of NHL